Yesterday, the COO, CSO of IsoRay (ISR), William Cavanagh, bought shares of ISR for $4,000.
Following this transaction William Cavanagh’s holding in the company was increased by 100% to a total of $3,900. In addition to William Cavanagh, 3 other ISR executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on IsoRay’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $1.56 million and GAAP net loss of $1.51 million. In comparison, last year the company earned revenue of $1.21 million and had a GAAP net loss of $1.55 million. Currently, IsoRay has an average volume of 114K.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.
